After US regulators finally gave their blessing for Bristol-Myers Squibb's $74bn takeover of Celgene, the acquisition was finally completed on 20 November. The completed acquisition creates a combined company with annual revenues in excess of $34bn, making it the sector’s fourth biggest firm behind Pfizer, Novartis and Roche.Source: PMLive 18/11/2019